📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. (2020)

First Author: Yeboah M

Attributed to: Engineering chimeric antigen receptor T Cells against human LILRB3 for treatment of acute myeloid leukaemia (AML) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1172/jci.insight.141593

PubMed Identifier: 32870822

Publication URI: http://europepmc.org/abstract/MED/32870822

Type: Journal Article/Review

Volume: 5

Parent Publication: JCI insight

Issue: 18

ISSN: 2379-3708